SUMMIT (COPD)
2016
Study to Understand Mortality and Morbidity in COPD
In 16,485 patients with moderate COPD and CVD or high CV risk, fluticasone furoate-vilanterol did not reduce all-cause mortality compared with placebo.
Result
Efficacy: All-cause mortalityHR 0.88 (95% CI 0.74-1.04) · P = 0.137
Below 1 favours fluticasone furoate-vilanterol, above 1 favours placebo.
Also reported: No effect on the composite CV outcome.
- Subtopic
- ICS/LABA, CV risk
- Design
- Multicentre RCT, 4-arm
- Relevance
- Supporting: context rather than must-know.
- Source
- Vestbo J, et al. Lancet. 2016;387(10030):1817-1826.doi 10.1016/S0140-6736(16)30069-1
Discussion & critique
Definitive negative trial of ICS/LABA mortality benefit in CV-enriched COPD; directly relevant to cardiology consultation.